GlassScriptPhysician profile
Thomas R Williams
NPI 1750345443
$4,423.98
in general payments reported to CMS, 2019-2025
24 companies · $468 in 2025
The $468 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,185 · 2020: $38.50 · 2021: $233 · 2022: $719 · 2023: $375 · 2024: $406 · 2025: $468.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,248.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,248.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Siemens Medical Solutions USA, INC. | $1,781.95 | 2019 | |
| Genentech USA, INC. | $496.61 | 2021-2025 | Vabysmo, Susvimo |
| Regeneron Healthcare Solutions, INC. | $260.93 | 2019-2025 | Eylea Hd, Eylea |
| Apellis Pharmaceuticals, INC. | $233.39 | 2022-2025 | Syfovre |
| Notal Vision, INC. | $218.06 | 2022-2025 | Foresee Home |
| Alimera Sciences, INC. | $216.65 | 2019-2024 | Iluvien, Yutiq |
| Johnson & Johnson Surgical Vision, INC. | $194.67 | 2022-2025 | Tecnis Iol |
| Genentech, INC. | $154.33 | 2019 | |
| Dutch Ophthalmic, USA | $147.86 | 2022-2024 | Tissueblue, Eva, Combined Machine |
| Abbvie INC. | $130.81 | 2022-2025 | Ozurdex |
| Regeneron Pharmaceuticals, INC. | $108.57 | 2019 | |
| Ani Pharmaceuticals, INC. | $86.59 | 2025 | Iluvien, Yutiq |
| Astellas Pharma US INC | $72.93 | 2023-2025 | Izervay |
| Novartis Pharmaceuticals Corporation | $54.29 | 2019-2021 | |
| Allergan, INC. | $40.52 | 2019-2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $40.12 | 2024-2025 | Xipere, Xiidra, Miebo |
| Kala Pharmaceuticals, INC. | $38.24 | 2021 | |
| Alcon Vision LLC | $35.52 | 2019 | |
| Rayner Intraocular Lenses Limited | $26.47 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Oyster Point Pharma, INC. | $24.88 | 2023 | Tyrvaya |
| Eyepoint US, INC. | $23.25 | 2022 | |
| Carl Zeiss Meditec USA, INC. | $18.88 | 2023 | Veracity Surgical |
| Sight Sciences, INC. | $18.46 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.